{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:05:33Z","timestamp":1783760733438,"version":"3.55.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Elen"},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Endoceutics"},{"name":"SST"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although spironolactone is an effective treatment for androgen-mediated cutaneous disorders, the potential sexual side-effects are poorly documented in current literature.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>The purpose of this study was to provide clinical evidence that spironolactone may be a cause of hormonally associated vestibulodynia and female sexual arousal disorder.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A database search of a vulvar disorders clinic revealed 7 cases in which spironolactone may have caused or contributed to dyspareunia and decreased arousal. In all cases, the patients stopped taking spironolactone and used a compounded estradiol 0.01%\/testosterone 0.1% gel to the vestibule twice daily. 2 cases are discussed to further illustrate these previously unreported side effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>Improvement in sexual function was determined after treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Examination of women taking spironolactone who presented with the complaints of introital dyspareunia revealed vulvar vestibular atrophy and tenderness, especially at the glandular ostia. After stopping spironolactone and applying a topical estrogen\/testosterone gel to the vestibule, all women had significant improvement in their vulvar atrophy, resolution of their dyspareunia, and improved sexual arousal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Use of spironolactone may be a cause of hormonally associated vestibulodynia and female sexual arousal disorder.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>The influence of spironolactone on vulvar health and sexual function is poorly documented in the medical literature. The strength of this paper is that it examines the potential deleterious side effects of this medication on female sexual function. However, the most significant limitation of this case series is that it was not a prospective, controlled study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although treatment of androgen-mediated cutaneous disorders is warranted, medical providers should be aware of the potential sexual side effects of this anti-androgenic medication.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2019.06.012","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T21:29:17Z","timestamp":1564003757000},"page":"1481-1483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Spironolactone May be a Cause of Hormonally Associated Vestibulodynia and Female Sexual Arousal Disorder"],"prefix":"10.1093","volume":"16","author":[{"given":"Leia","family":"Mitchell","sequence":"first","affiliation":[{"name":"The Centers for Vulvovaginal Disorders , Washington, DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi","family":"Govind","sequence":"additional","affiliation":[{"name":"The Centers for Vulvovaginal Disorders , Washington, DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa","family":"Barela","sequence":"additional","affiliation":[{"name":"The Centers for Vulvovaginal Disorders , Washington, DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"The Centers for Vulvovaginal Disorders , Washington, DC , USA"},{"name":"Department of Obstetrics and Gynecology , Washington, DC , USA"},{"name":"The George Washington University School of Medicine and Health Sciences , Washington, DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"2023010721202659800_bib1","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaad.2018.08.061","article-title":"Androgens in women: Hormone modulating therapies for skin disease (Part II)","volume":"6","author":"Azarchi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2023010721202659800_bib2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0015-0282(02)02969-2","article-title":"Female androgen insufficiency: The Princeton consensus statement on definition, classification, and assessment","volume":"77","author":"Bachmann","year":"2002","journal-title":"Fertil Steril"},{"key":"2023010721202659800_bib3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.sxmr.2018.03.005","article-title":"Role of androgens in female genitourinary tissue structure and function: Implications in the genitourinary syndrome of menopause","volume":"6","author":"Traish","year":"2018","journal-title":"Sex Med Rev"},{"key":"2023010721202659800_bib4","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1111\/j.1743-6109.2012.02848.x","article-title":"The effects of hormonal contraceptives on female sexuality: A review","volume":"9","author":"Burrows","year":"2012","journal-title":"J Sex Med"},{"key":"2023010721202659800_bib5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/1523-1747.ep12472325","article-title":"Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5 alpha-dihydrotestosterone in vitro","volume":"100","author":"Akamatsu","year":"1993","journal-title":"J Invest Dermatol"},{"key":"2023010721202659800_bib6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/AOG.0000000000001359","article-title":"2015 ISSVD, ISSWSH and IPPS Consensus terminology and classification of persistent vulvar pain and vulvodynia","volume":"127","author":"Bornstein","year":"2016","journal-title":"Obstet Gynecol"},{"key":"2023010721202659800_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40257-016-0245-x","article-title":"Oral spironolactone for acne vulgaris in adult females: A hybrid systematic review","volume":"18","author":"Layton","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"2023010721202659800_bib8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1743-6109.2011.02597.x","article-title":"Sexual behavior and oral contraception: A pilot study","volume":"9","author":"Battalgia","year":"2012","journal-title":"J Sex Med"},{"key":"2023010721202659800_bib9","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1111\/jsm.12668","article-title":"Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia","volume":"11","author":"Goldstein","year":"2014","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519312718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519312718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/9\/1481\/48477016\/jsm_16_9_1481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/9\/1481\/48477016\/jsm_16_9_1481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T21:21:45Z","timestamp":1673126505000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/16\/9\/1481\/6966852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":9,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,7,24]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.06.012","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spironolactone May be a Cause of Hormonally Associated Vestibulodynia and Female Sexual Arousal Disorder","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}